Synaptogenix announces conference call to discuss aaic abstract findings

New york, july 21, 2021 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will hold a conference call for investors to discuss its abstract presented at the alzheimer's association international conference. the call will take place on monday, july 26 th at 4:15pm et and will be hosted by the company's chief executive officer, dr. alan tuchman, and its president and chief science officer, dr. daniel alkon.
SNPX Ratings Summary
SNPX Quant Ranking